98%
921
2 minutes
20
Previous studies indicated per- and poly-fluoroalkyl substances (PFAS) were related to uric acid and hyperuricemia risk, but evidence for the exposure-response (E-R) curves and combined effect of PFAS mixture is limited. Moreover, the potential mediation effect of kidney function was not assessed. Hence, we conducted a national cross-sectional study involving 13,979 US adults in NHANES 2003-2018 to examine the associations of serum PFAS with uric acid and hyperuricemia risk, and the mediation effects of kidney function. Generalized linear models and E-R curves showed positive associations of individual PFAS with uric acid and hyperuricemia risk, and nearly linear E-R curves indicated no safe threshold for PFAS. Weighted quantile sum regression found positive associations of PFAS mixture with uric acid and hyperuricemia risk, and PFOA was the dominant contributor to the adverse effect of PFAS on uric acid and hyperuricemia risk. Causal mediation analysis indicated significant mediation effects of kidney function decline in the associations of PFAS with uric acid and hyperuricemia risk, with the mediated proportion ranging from 19 % to 57 %. Our findings suggested that PFAS, especially PFOA, may cause increased uric acid and hyperuricemia risk increase even at low levels, and kidney function decline plays a crucial mediation effect.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jhazmat.2024.134312 | DOI Listing |
Kardiologiia
September 2025
Department of Cardiology, The Ninth Medical Center, Chinese PLA General Hospital.
Background Hyperuricemia (HUA) frequently coexists with coronary artery disease (CAD) and is linked to adverse cardiovascular outcomes. The long-term impact of urate-lowering therapy (ULT) on clinical outcomes, including all-cause mortality and major adverse cardiovascular events (MACEs), in CAD patients after percutaneous coronary intervention (PCI) has not been determined. That was the aim of this study.
View Article and Find Full Text PDFClin Kidney J
September 2025
Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Background: This study aimed to evaluate the efficacy and safety of telitacicept versus mycophenolate mofetil (MMF) in high-risk progressive immunoglobulin A nephropathy (IgAN).
Methods: This retrospective, multicentre cohort study included patients with high-risk progressive IgAN who received telitacicept or MMF therapy, both combined with low-dose steroids. Clinical data were collected from treatment initiation to 12 months.
Nutr Metab Cardiovasc Dis
July 2025
Department of Gastroenterology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315040, PR China. Electronic address:
Background And Aims: Obesity-related non-alcoholic fatty liver disease (NAFLD) and serum high-sensitivity C-reactive protein (hs-CRP) are known to be associated to some extent. Nevertheless, this relationship remains unclear in non-obese individuals.
Methods And Results: A prospective cohort study was conducted using data from the health check ups of employees at Zhenhai Refining and Chemical Hospital in Ningbo City.
J Clin Neurosci
September 2025
Azienda Sanitaria Provinciale Catania, Catania, Italy. Electronic address:
J Appl Lab Med
September 2025
Department of Pathology, UC San Diego Health, San Diego, CA, United States.
Background: While clinical laboratories routinely perform automated chemistry assays on approved specimens (e.g., plasma and serum), the FDA has not evaluated the validity of these assays for nonapproved specimens (e.
View Article and Find Full Text PDF